152 related articles for article (PubMed ID: 23355202)
1. Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods.
Jing X; Li QK; Bedrossian U; Michael CW
Am J Clin Pathol; 2013 Feb; 139(2):177-82. PubMed ID: 23355202
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block.
Gong Y; Sun X; Michael CW; Attal S; Williamson BA; Bedrossian CW
Diagn Cytopathol; 2003 Jan; 28(1):1-5. PubMed ID: 12508174
[TBL] [Abstract][Full Text] [Related]
3. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
Ueda J; Iwata T; Ono M; Takahashi M
Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
6. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of clot examination for malignant cells in serous effusions.
Jalal R; Aftab K; Hasan SH; Pervez S
Cytopathology; 2009 Aug; 20(4):231-4. PubMed ID: 18627403
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunocytochemical sensitivity between formalin-fixed and alcohol-fixed specimens reveals the diagnostic value of alcohol-fixed cytocentrifuged preparations in malignant effusion cytology.
Ikeda K; Tate G; Suzuki T; Mitsuya T
Am J Clin Pathol; 2011 Dec; 136(6):934-42. PubMed ID: 22095380
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
10. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
11. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of immunohistochemistry staining and cytologic diagnosis by using cell block sections prepared with effusion fluid cytology specimens].
Mao YY; Yang M; Liu DG; Lin MH; Zhang LQ; Chen ZQ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):547-50. PubMed ID: 20021967
[TBL] [Abstract][Full Text] [Related]
13. Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation.
Pu RT; Giordano TJ; Michael CW
Cancer; 2008 Oct; 114(5):300-6. PubMed ID: 18798226
[TBL] [Abstract][Full Text] [Related]
14. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
Sundling KE; Cibas ES
Cancer Cytopathol; 2018 Aug; 126 Suppl 8():590-598. PubMed ID: 30156768
[TBL] [Abstract][Full Text] [Related]
15. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
[TBL] [Abstract][Full Text] [Related]
16. Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology.
Bedrossian CW
Diagn Cytopathol; 1998 Feb; 18(2):141-9. PubMed ID: 9484644
[No Abstract] [Full Text] [Related]
17. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
18. [Cytodiagnosis and cytomorphologic analysis of hematolymphoid malignancy in serous effusion: a study of 23 cases].
He SR; Peng WX; Sun MJ; Yang L; He L; Su XL; He Q; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):691-5. PubMed ID: 23302312
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry.
Fetsch PA; Simsir A; Brosky K; Abati A
Diagn Cytopathol; 2002 Jan; 26(1):61-6. PubMed ID: 11782091
[TBL] [Abstract][Full Text] [Related]
20. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
Schofield K; D'Aquila T; Rimm DL
Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
